Antisense Oligonucleotides Against VR1

ABSTRACT

Antisense oligodeoxynucleotides against VR1, corresponding nucleotide constructs, cells containing said nucleotide constructs, pharmaceutical and diagnostic substances, uses thereof in pain therapy, and methods for diagnosing symptoms related to VR1 and for identifying pain-modulating substances.

CROSS REFERENCE TO RELATED APPLICATIONS

The present application is a division of application Ser. No.10/376,341, filed Mar. 3, 2003, now U.S. patent Ser. No. ______, whichin turn is a continuation of International Patent Application No.PCT/EP01/10081, filed Aug. 31, 2001, designating the United States ofAmerica and published in German as WO 02/18407 A2, the entire disclosureof which is incorporated herein by reference. Priority is claimed basedon Federal Republic of Germany Patent Application Nos. 100 43 674.9,filed Sep. 2, 2000, and 100 43 702.8, filed Sep. 4, 2000.

BACKGROUND AND SUMMARY OF THE INVENTION

The invention relates to antisense oligodeoxynucleotides against VR1, tocorresponding nucleotide constructs, to cells, pharmaceuticalpreparations and diagnostic preparations containing these, to the usethereof in pain therapy and to methods for diagnosing symptomsassociated with VR1 and for identifying pain-modulating substances.

The effective treatment of pain is a major challenge to molecularmedicine. Acute and transient pain is an important bodily signalprotecting people from severe injury by their environment or byoverloading their body. In contrast, chronic pain, which lasts longerthan the cause of the pain and the anticipated time frame for cure, hasno known biological function and affects hundreds of millions of peopleworldwide. In the Federal Republic of Germany alone, some 7.5 millionpeople suffer from chronic pain. Unfortunately, pharmacologicaltreatment of chronic pain is still unsatisfactory and thus remains achallenge to current medical research. Currently existing analgesicsoften have an inadequate action and sometimes have severe side effects.

The search is thus now on for new targets or endogenous body structureswhich appear to provide a way of exerting pain-modulating action, forexample using low molecular weight active substances or other compoundssuch as antisense oligodeoxynucleotides (ODN), in particular for thetreatment of chronic pain.

The vanilloid receptor subtype 1 (VR1, also known as the capsaicinreceptor) cloned by Caterina et al. (1997) is a promising starting pointfor the development of new analgesic drugs. This receptor is a cationchannel which is predominantly expressed by primary sensory neurons(Catarina et al. 1997). VR1 is activated by capsaicin, a component ofchillies, heat (>43° C.) and a low pH as a result of tissue injury, andbrings about a calcium influx in primary afferents. VR1 knockout micedid not develop thermal hyperalgesia after tissue injury or inflammation(Caterina et al., 2000; Davis et al., 2000).

Antisense oligodeoxynucleotides, ribozymes and other catalytic nucleicacids may be used for the treatment, in particular of chronic pain, bydegrading or modifying the mRNA of selected targets, in the case of thepresent invention the above-described VR1, to down-regulate theexpression thereof and thus reduce the number of receptors per cell. TheODN attach themselves to the mRNA, so firstly blocking translation andsecondly initiating degradation of the mRNA by RNase H, which cleavesthe DNA/RNA duplex. Porreca et al. (1999) were able to demonstrate thatintrathecally administered ODNs against the PN3/SNS channel in ratsprevent the development of hyperalgesia and allodynia due to chronicnerve or tissue damage.

Even once the sequence of VR1 is known, effective blocking and cleavageof the mRNA in particular depends upon the selection of the correctantisense oligodeoxynucleotides, ribozymes and other catalytic nucleicacids. The target's mRNA is usually folded and only a few sites areaccessible for attachment and subsequent cleavage. Nothing is known inthe prior art about how to select the ODN correctly.

DESCRIPTION OF THE INVENTION

The object of the present document was accordingly to develop antisenseoligodeoxynucleotides and catalytic nucleic acids together withcorresponding ribozymes against the mRNA of the vanilloid receptor. Thepresent invention accordingly provides an oligonucleotide containing orcorresponding to a base sequence according to one of sequences (b) to(j) in each of FIG. 1, 2, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 16or a sequence differing therefrom by at most one different base, whereinthe base difference is not located in the sequence domain shown insequence (a). For the purposes of the present invention, oligonucleotidemeans a molecule having between 2 and 40 nucleotides.

The present invention also provides an oligonucleotide containing orcorresponding to a base sequence according to one of sequences (b) to(j) in one of FIG. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or16.

The present invention also provides an oligonucleotide containing orcorresponding to a base sequence according to (k) in one of FIG. 1, 2,4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 16, or a sequence differingtherefrom by at most two different bases, preferably one, wherein thebase difference(s) is (are) not located in the sequence domain shown in(a).

The present invention also provides an oligonucleotide containing orcorresponding to a base sequence according to (k) in each of FIG. 1, 2,3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 16.

The present invention preferably also provides an oligonucleotide whichhas a length of 15 to 30, preferably of 15 to 25, in particular 17 to19, or exactly 18, nucleotides.

The present invention also preferably provides an oligonucleotide(hereinafter denoted oligonucleotide A) according to one of theabove-stated oligonucleotide forms in which, optionally with onedifferent base, the base sequence contained in the oligonucleotides orcorresponding thereto may be found in one of FIG. 1, 2, 3, 4, 9, 10, 11,12, 15 or 16. These in particular comprise oligonucleotides which havebeen found to be particularly effective or contain corresponding,optionally slightly different, sequences, which bind strongly to themRNA of VR1 (see oligos V15, V30, V2, V16 and V4 or the correspondinghuman sequences).

The present invention also preferably provides an oligonucleotide(hereinafter denoted oligonucleotide B) in which, optionally with onedifferent base, the base sequence contained in the oligonucleotides orcorresponding thereto may be found in one of FIG. 1, 2, 3, 4, 11 or 12,preferably 1, 3 or 11, in particular 1 or 3.

The present invention preferably provides an oligonucleotide accordingto the invention which comprises at least one modified or unmodifiedribose, at least one modified or unmodified phosphodiester bond and/orat least one modified or unmodified base.

The present invention preferably provides an oligonucleotide accordingto the invention, in which at least one of the nucleotides, inparticular two or more of the nucleotides, are “locked nucleic acids”(LNAs) or at least one of the nucleotides, in particular all of thenucleotides, are phosphorothioates, preferably one in which two or moreof the nucleotides are “locked nucleic acids (LNAs). “Locked nucleicacids” (LNAs) are ribonucleotides which contain a methylene bridge whichjoins the 2′ oxygen of the ribose with the 4′ carbon (see FIG. 27).Braasch D. A. and Corey, D. R. (2001), Locked nucleic acids (LNA);fine-tuning the recognition of DNA and RNA. Chem. Biol. 8, 1-7, providean overview of LNAs. This article is herein explicitly incorporated byreference in its entirety. LNAs are available commercially, for example,from the company Proligo, Boulder, Colo., USA. Phosphorothioates arealso known to the person skilled in the art and may be ordered, forexample, from MWG-Biotech AG, Ebersberg, Germany.

Preferred oligonucleotides are those in which the LNAs are located atthe 5′ and 3′ end of the oligonucleotide, preferably in each case thefinal 2-5 nucleotides, in particular in each case the final 3 or 4nucleotides, on the 3′ and 5′ end of the oligonucleotide are LNAs.Preferably, oligonucleotides of the invention have >6, in particular >8contiguous nucleotides in the oligonucleotide that are not LNAs.Preferably, of the nucleotides shown in the sequence domain according tothe particular, sequence (a) of the oligonucleotide according to one ofFIGS. 1 to 16, at most one or none of the nucleotides is in each case anLNA.

In the case of oligonucleotides modified with LNAs or phosphorothioates,it is particularly preferred if the oligonucleotide is anoligonucleotide A according to the invention or an oligonucleotide Baccording to the invention, preferably an oligonucleotide B according tothe invention (see above).

In general, the present invention specifically provides nucleic acids,in particular oligonucleotides, in which two or more of the nucleotidesare “locked nucleic acids” (LNAs), in which the LNAs are on the 5′ and3′ end of the oligonucleotide, preferably in each case the final 2-5nucleotides, in particular in each case the final 3 or 4 nucleotides, onthe 3′ and 5′ end of the oligonucleotide are LNAs, and/or in which >6,in particular >8 contiguous nucleotides in the oligonucleotide are notLNAs. The embodiments previously explained with regard to the LNAs alsoapply to this subject matter of the invention.

The present invention also preferably provides a polynucleotideconstruct containing at least one oligonucleotide according to theinvention. Polynucleotide construct should here be taken to have a verywide meaning. It includes RNA and DNA and nucleotides from a length ofat least 20 nucleotides. A “recombinant” polynucleotide construct shouldhere be taken to be a general designation for any kind of DNA or RNAmolecules which have been obtained by in vitro linkage of DNA or RNAmolecules. Polynucleotide is taken to have the following meaning: theunderlying nucleotide is a fundamental nucleic acid building blockessentially consisting of nucleic base, pentose and phosphoric acid.This corresponds to a high molecular weight polynucleotide prepared fromtwo or more nucleotides linked together by phosphoric acid/pentoseesterification. However, the invention also includes modifiedpolynucleotides which, while they retain the sequence of bases, have amodified backbone instead of phosphoric acid/pentose.

The present invention also preferably provides a polynucleotideconstruct containing in two separate domains, two nucleotidesubsequences Fragment I and Fragment III according to one of sequences(l)-(n) or the two nucleotide subsequences helix I and helix IIIaccording to one of sequences (o)-(q) in one of FIG. 1, 3, 4, 5, 6, 7,8, 9, 11, 12, 13 or 15, or nucleotide subsequences differing from thesenucleotide subsequences in each case by at most one base. Furtherdetails relating to the division of the two domains may be found in FIG.24 (helix I and helix III/ribozyme) and in Santoro et al. (1997) FIG. 2,p. 4264 (Fragment I and Fragment III/DNA enzyme), the entire content ofthe latter is herein explicitly incorporated by reference.

The present invention also preferably provides a polynucleotideconstruct which codes for at least one oligonucleotide according to theinvention. This in particular comprises DNA to be read out or a vectorcontaining DNA or RNA, the product of which is or may be anoligonucleotide according to the invention.

The present invention also particularly preferably provides apolynucleotide construct according to the invention which comprises aribozyme, a DNA enzyme, a vector, in particular an expression vector, ora peptide nucleic acid (PNA).

The following definitions apply for the purposes of the presentinvention:

-   -   Cloning vector: A general name for nucleic acid molecules acting        as vectors or carriers for foreign genes or parts thereof during        cloning.    -   Expression vector: A name for specially constructed cloning        vectors which, once inserted in a suitable host cell, permit the        transcription and translation of the foreign gene cloned into        the vector.    -   PNA: Standard international abbreviation for peptide nucleic        acids. Peptide-linked amino acids here form a chain, the amino        acids bearing as side chain a base capable of hybridisation with        DNA or RNA.    -   Sequence: A succession of nucleotides or amino acids. For the        purposes of the present invention, sequence is intended to mean        nucleic acid sequence.    -   Ribozyme: A name for a catalytically active ribonucleic acid        (for example ligase, endonuclease, polymerase, exonuclease), see        for example hammerhead ribozyme according to FIG. 24 or 25 and        the description of the Figures or see Vaish, N. K. et al.        (1998), Nucl. Acid Res. 26, 5237-5242.    -   DNA enzyme: A name for a DNA molecule which exhibits catalytic        activity (for example ligase, endonuclease, polymerase,        exonuclease), see for example DNA enzyme 10-23 according to FIG.        26 and the description of the Figure, or see Santoro and        Joyce (1997) Proc. Natl. Acad. Sci. USA 94, 4262-4266.    -   Catalytic RNA/DNA: A general name for ribozymes or DNA enzymes        (see above).

The present invention also preferably provides a polynucleotideconstruct containing in two separate domains two nucleotidesubsequences, as described above, wherein said construct comprises aribozyme, preferably a “hammerhead” ribozyme, or a DNA enzyme,preferably a type 10-23 or 12-32 DNA enzyme. It is particularlypreferred and selected if said construct comprises a DNA enzymecontaining at least the nucleotide subsequences Fragment I and FragmentIII according to one of sequences (l) to (n), preferably (n), in one ofFIG. 1, 3, 4, 5, 6, 7, 8, 9, 11, 12 or 13; preferably 1, 3, 7 or 11, inparticular 1 or 3; or preferably 4, 6, 8 or 12, in particular 4 or 12.

It is particularly preferred and selected if said polynucleotideconstruct comprises a ribozyme containing at least the nucleotidesubsequences helix I and helix III according to one of sequences (o) to(q), preferably (o), in one of FIGS. 1, 3, 4, 5, 6, 8, 11 or 12;preferably 1, 3 or 11, in particular 11; or preferably 4, 6, 8 or 12, inparticular 4 or 12.

Specifically, a preferred embodiment may in particular be found in FIGS.24 and 25. FIG. 24 is a general diagram of a “hammerhead” ribozyme afterVaish, N. K. et al. (1998), Nucl. Acid Res. 26, 5237-5242 with the“recognition arms” helix I and helix III, into which the helices I andIII according to the invention according to sequences (o)-(q) in one ofFIG. 1, 3, 4, 5, 6, 7, 8, 9, 11, 12, 13 or 15 are inserted, in order toobtain the hammerhead ribozymes according to the invention. The fragmenthelix I here replaces in each case in one of FIG. 1, 3, 4, 5, 6, 7, 8,9, 11, 12, 13 or 15 the desired nucleotides in helix I according to FIG.24 in such a manner that the first nucleotide on the 3′ end of helix Iin each case in one of FIG. 1, 3, 4, 5, 6, 7, 8, 9, 11, 12, 13 or 15replaces the first desired nucleotide “N” on the 3′ end of helix I ofFIG. 24 and the following desired nucleotides “N” in helix I, FIG. 24towards the 5′ end are replaced by the nucleotides which are shown inone of sequences (o) to (q) of helix I in each case in one of FIG. 1, 3,4, 5, 6, 7, 8, 9, 11, 12, 13 or 15. The nucleotides “A” and “C” on the5′ end of helix III in one of FIG. 1, 3, 4, 5, 6, 7, 8, 9, 11, 12, 13 or15 in each case replace the nucleotides “A” and “C” in helix III in FIG.24, and the following desired nucleotides “N” in helix III, FIG. 24 arereplaced in the 5′ end direction by the nucleotides which are shown inone of sequences (o)-(q), helix III, in each case in one of FIG. 1, 3,4, 5, 6, 7, 8, 9, 11, 12, 13 or 15. FIG. 25 shows a specific example.The hammerhead ribozyme V16 (7/7) is derived from FIG. 24 and FIG. 11.The designation ribozyme V16 (7/7) here means that the enzyme isoriented towards the GUC site of oligo V16 and contains 7 nucleotides ineach of the “recognition arms” (helix I and helix III), in this caseaccording to helix I and helix III of sequence (o) in FIG. 11. The sameapplies to all ribozymes according to sequences (o to q) in each case inone of FIG. 1, 3, 4, 5, 6, 7, 8, 9, 11, 12, 13 or 15.

Specifically, a preferred embodiment may in particular be found in FIG.26. FIG. 26 is a general diagram of a type “10-23” DNA enzyme accordingto Santoro et al., 1997, FIG. 2, p. 4264. The upper strand marked withan arrow is the RNA strand to be cleaved, the arrow showing the cleavagesite, while the lower strand is a representation of the DNA enzyme. Withregard to the present application, in the upper strand the “Y”=“U” andthe “R”=“G”, a “C” being located 3′-wards from “Y”. The cleavage site onthe upper strand is thus a GUC site (see above). Correspondingly, “R” inthe lower strand=“A”, a “G” correspondingly being located 5′-wards from“R” in the lower strand. This is followed 5′-wards by the furthernucleotides from Fragment I according to sequences (l to n) in each casein one of FIG. 1, 3, 4, 5, 6, 7, 8, 9, 11, 12, 13 or 15, i.e. 5 furthernucleotides in sequence l, 6 further nucleotides in sequence m and 7further nucleotides in sequence n. In Fragment III according to FIG. 25,the second with the RNA base-paired fragment, the unpaired “A” onFragment III is then directly followed from the 5′ direction 3′-wards bythe nucleotides from Fragment III according to sequences (l to n) ineach case in one of FIG. 1, 3, 4, 5, 6, 7, 8, 9, 11, 12, 13 or 15, i.e.7 further nucleotides in sequence l, 8 further nucleotides in sequence mand 9 further nucleotides in sequence n. Fragment III and Fragment I arethe “recognition arms” of the DNA enzyme (see Example 3 below).

The type “10-23” DNA enzyme for sequence n according to FIG. 1 which isparticularly preferred for the purposes of the invention would thus havethe following sequence, wherein the underlined fragment would bebase-paired with the RNA:

(SEQ ID NO: 249) ATGTCATGA(=R)-GGCTAGCTACAACGA-GGTTAGGGG

This DNA enzyme was named V15 (9/9), wherein the name indicates that theenzyme is oriented towards the GUC site of oligo V15 and the“recognition arms” in each case contain 9 nucleotides (Fragment I andIII), for example according to Fragment I and Fragment III of sequence(n) in FIG. 1. The same applies to all DNA enzymes according tosubpoints (l to n) in each case in one of FIG. 1, 3, 4, 5, 6, 7, 8, 9,11, 12, 13 or 15.

The present invention also preferably provides a polynucleotideconstruct according to the invention, wherein it comprises at least onemodified or unmodified ribose, at least one modified or unmodifiedphosphodiester bond and/or at least one modified or unmodified base.

The present invention also preferably provides an oligonucleotideaccording to the invention or polynucleotide construct according to theinvention, wherein it is bound on a support, in particular a protein,preferably tet-, transportin or ferritin, and/or is packaged in aliposome.

The present invention also preferably provides a cell containing atleast one oligonucleotide according to the invention and/or apolynucleotide construct according to the invention.

The present invention also preferably provides a pharmaceuticalpreparation containing at least one oligonucleotide according to theinvention, a polynucleotide construct according to the invention and/ora cell according to the invention, optionally together with a suitableauxiliary substance and/or additive. The pharmaceutical preparationsaccording to the invention may be administered in the form of solutionsfor injection, drops or juice, as semi-solid dosage forms in the form ofgranules, tablets, pellets, patches, capsules, dressings or aerosolsand, in addition to the at least one subject matter of the invention,they also optionally contain, depending upon the pharmaceuticalpresentation, excipients, fillers, solvents, diluents, colorants and/orbinders. Selection of the auxiliary substances and the quantitiesthereof which are to be used depends upon whether the pharmaceuticalpreparation is to be administered orally, perorally, parenterally,intravenously, intraperitoneally, intradermally, intramuscularly,intranasally, buccally, rectally or topically, for example ontoinfections of the skin, mucous membranes or eyes. Preparations in theform of tablets, coated tablets, capsules, granules, drops, succi andsyrups are suitable for oral administration, while solutions,suspensions, easily reconstitutible dried preparations and sprays aresuitable for parenteral, topical and inhalatory administration. Subjectmatters of the invention in a depot in dissolved form or in a dressing,optionally with the addition of skin penetration promoters, are suitablepercutaneous administration preparations. Orally or percutaneouslyadministrable formulations may release the subject matters of theinvention in delayed manner. The quantity of active substance to beadministered to the patient varies as a function of patient weight, modeof administration, the indication and the severity of the condition. 2to 500 mg/kg of at least one subject matter of the invention areconventionally administered. Especially if the pharmaceuticalpreparation is to be used for gene therapy, suitable auxiliarysubstances and additives which it is advisable to use are, for example,a physiological saline solution, stabilizers, proteinase inhibitors,DNAse inhibitors etc.

The present invention also preferably provides a diagnostic aidcontaining at least one oligonucleotide according to the invention, apolynucleotide construct according to the invention and/or a cellaccording to the invention, optionally together with suitable additives.

The following definitions apply:

-   -   Pharmaceutical preparation: A substance as defined in Article 1        §2 of the German Drug Law (Arzneimittelgesetz, AMG). In other        words, substances or preparations made from substances which, by        application on or in the human or animal body are intended    -   1. to cure, alleviate, prevent or diagnose diseases, suffering,        bodily injury or sickness symptoms,    -   2. to diagnose the nature, the state or the functions of the        body or mental health conditions,    -   3. to replace active substances or body fluids produced in the        human or animal body,    -   4. to ward off pathogens, parasites or substances alien to the        body or to destroy them or to render them harmless or    -   5. to influence either the nature, the state or the functions of        the body or mental health conditions.    -   Diagnostic aid: A compound or method which may be used to        diagnose a disease.

The present invention also preferably provides the use of at least oneoligonucleotide according to the invention, a polynucleotide constructaccording to the invention and/or a cell according to the invention forthe production of a pharmaceutical preparation for the treatment ofpain, in particular chronic pain, tactile allodynia, thermally inducedpain and/or inflammatory pain.

The present invention also preferably provides the use of at least oneoligonucleotide according to the invention, a polynucleotide constructaccording to the invention and/or a cell according to the invention forthe production of a pharmaceutical preparation for the treatment ofurinary incontinence; also of neurogenic bladder symptoms; pruritus,tumors, inflammation; in particular VR1 receptor-associated inflammationwith symptoms such as asthma; together with any disease symptomsassociated with VR1.

The present invention also preferably provides the use of at least oneoligonucleotide according to the invention, a polynucleotide constructaccording to the invention and/or a cell according to the invention forgene therapy, preferably in vivo or in vitro gene therapy. Gene therapyis taken to be a type of therapy in which, by the introduction ofnucleic acids into cells, an effector gene product, usually a protein,but also an antisense oligodeoxynucleotide, is expressed. A fundamentaldistinction is drawn between in vivo and in vitro methods. In in vitromethods, cells are removed from the organism and transfected withvectors ex vivo before subsequently being introduced back into the sameorganism or a different one. In in vivo gene therapy, vectors, forexample for combating tumors, are administered systemically (for examplevia the bloodstream) or directly into the tumor.

The present invention also preferably provides a process for theidentification of pain-modulating substances, characterized in thatidentification is made by quantification of the binding of at least one,preferably labelled, oligonucleotide according to the invention or atleast one polynucleotide construct onto an RNA.

The present invention also preferably provides a process for theidentification of pain-modulating substances comprising the followingprocess steps:

-   -   (a) genetic engineering manipulation of at least one cell (test        cell) with at least one oligonucleotide according to the        invention and/or a polynucleotide construct according to the        invention,    -   (a′) parallel genetic engineering manipulation, of at least one        identical cell (control cell), which manipulation is either        -   not carried out,        -   carried out in parallel with the oligonucleotide or            polynucleotide construct, or        -   carried out with a modified oligonucleotide or            polynucleotide construct which is other than one according            to the invention,    -   (b) parallel incubation of a substance to be tested under        suitable conditions with at least one test cell and at least one        control cell and/or a preparation made from such a cell, which        has synthesized at least one receptor protein selected from the        vanilloid receptor family, preferably the VR-1 receptor,    -   (c) measurement of the binding of the test substance onto the        protein synthesized by the cells or measurement of at least one        functional parameter modified by binding of the test substance        onto the receptor protein,    -   (d) identification of the substances by the extent of the        difference between the measured value for the test cell and that        for the control cell.

The term pain-modulating here refers to a potentially regulatinginfluence upon physiological pain phenomena, in particular to ananalgesic action. The term substance comprises any compound suitable asa pharmaceutical active substance, thus in particular low molecularweight active substances, but also others such as nucleic acids, fats,sugars, peptides or proteins such as antibodies. Incubation undersuitable conditions should here be taken to mean that the substance tobe investigated is capable of reacting in an aqueous medium for adefined period prior to measurement with the cell or the correspondingpreparation. The aqueous medium may be temperature-controlled, forexample between 4° C. and 40° C., preferably at room temperature or at37° C. The incubation time may be varied between a few seconds andseveral hours, depending upon how the substance interacts with thereceptor. Times of between 1 min and 60 min are, however, preferred. Theaqueous medium may contain suitable salts and/or buffer systems, suchthat a pH of between 6 and 8, preferably pH 7.0-7.5 prevails in themedium during incubation. Suitable substances, such as coenzymes,nutrients etc., may additionally be added to the medium. Suitableconditions may readily be established by the person skilled in the artas a function of the substance-receptor interaction which is to beinvestigated on the basis of his/her experience, the literature or a fewsimple preliminary tests, so that the clearest possible measured valueis obtained from the process. A cell which has synthesized a receptor isa cell which has already endogenously expressed this receptor or onewhich has been modified by genetic engineering in such a manner that itexpresses this receptor and consequently contains the receptor prior tothe beginning of the process according to the invention. The cells maybe cells from possibly immortalized cell lines or be native cellsoriginating and isolated from tissues, wherein cell aggregation hasusually been broken down. The preparation made from these cells inparticular comprises cell homogenates, the cytosol, a membrane fractionof the cells with membrane fragments, a suspension of isolated cellorganelles etc.

The yardstick which permits the identification of interesting substancesis either binding to the receptor, which may, for example, be detectedby displacement of a known ligand or by the extent of substance binding,or the modification of a functional parameter due to the interaction ofthe substance with the receptor. This interaction may in particularinvolve regulation, inhibition and/or activation of receptors, ionchannels and/or enzymes, while modified functional parameters may be,for example, gene expression, ion concentration, pH or membranepotential or modification of enzyme activity or the concentration ofsecondary messengers. The following definitions apply:

-   -   subjected to genetic engineering manipulation: manipulation of        cells, tissues or organisms in such a manner that genetic        material is introduced or altered therein    -   endogenously expressed: expression of a protein exhibited by a        cell line under suitable culture conditions, without expression        of this corresponding protein having been effected by genetic        engineering manipulation.

Another preferred embodiment of the present process provides that thecell has already been subjected to genetic engineering manipulationbefore process steps (a) and (a′).

Another preferred embodiment of the present process provides that thegenetic engineering manipulation permits the measurement of at least oneof the functional parameters modified by the test substance.

Another preferred embodiment of the present process provides that thegenetic engineering manipulation results in the expression of a form,not endogenously expressed in the cell, of a member of the vanilloidreceptor family, preferably the VR-1 receptor, or in the introduction ofa reporter gene.

Another preferred embodiment of the present process provides thatbinding is measured by the displacement of a known, labelled ligand of amember of the vanilloid receptor family, preferably the VR-1 receptor.

Another preferred embodiment of the present process provides that thereis an elapse of not less than 8 h, preferably not less than 12 h, inparticular not less than 24 h between the parallel process steps (a) and(a′), and process step (b).

The present invention also preferably provides a process for thediagnosis of clinical conditions which are associated with modifiedexpression of genes of the vanilloid receptor family, which process ischaracterized in that the diagnosis is made by means of quantificationof the binding of an oligonucleotide according to the invention and/orat least one polynucleotide construct onto an RNA.

The oligonucleotides and also the polynucleotide constructs are producedby processes known to the person ordinarily skilled in the art.Nucleotides, in particular also oligonucleotides, are synthesized in themanner of the Merrifield synthesis on an insoluble support (H. G. Gassenet al., Chemical and Enzymatic Synthesis of Gene Fragments (VerlagChemie, Weinheim 1982)) or in another manner (Beyer/Walter; Lehrbuch derOrganischen Chemie, 20th edition, (S. Hirzel Verlag, Stuttgart 1984),pp. 816 et seq.).

The present invention also provides a process for the treatment, inparticular treatment for pain, of a non-human mammal or human requiringtreatment for pain, in particular chronic pain, by administration of apharmaceutical preparation according to the invention, in particularsuch a preparation containing an oligonucleotide according to theinvention and/or a polynucleotide construct according to the invention.The invention also provides corresponding processes for the treatment ofpruritus and/or urinary incontinence.

The following Examples and Figures are intended to illustrate theinvention, but without restricting the subject matter of the inventionthereto.

BRIEF DESCRIPTION OF THE DRAWINGS

Figures, Figure and Figure should be regarded as synonymous. In relationto the Figures, the terms subtype and sequence are likewise synonymous.An “X” in the sequences shown denotes any desired complementarynucleotide to the corresponding base on the mRNA of VR1.

FIG. 1 lists general nucleotide sequences starting from an antisenseoligodeoxynucleotide sequence against VR1 mRNA from the rat, herefrequently designated oligo V15, oligonucleotide no. 15 or V15.Sequences or subtypes (a)-(j) show truncated fragments from thisantisense oligodeoxynucleotide sequence. Sequence (k) shows thefull-length antisense oligodeoxynucleotide sequence with which the“messenger walk screening” was carried out. Sequences (l)-(n) each showstwo nucleotide subsequences (Fragment I and Fragment III) starting fromthe full-length antisense oligodeoxynucleotide sequence, which eachcomprises non-overlapping subdomains of this sequence or correspondingsequence thereto, is usually divided at or in the GAC region and, incertain polynucleotide constructs, in particular DNA enzymes, and occursin two separate domains, the “recognition arms.” Subtypes (o)-(q) eachshows two nucleotide subsequences (helix I and helix III) starting fromthe full-length antisense oligodeoxynucleotide sequence (in this case asRNA), which each comprises non-overlapping subdomains of this sequenceor a corresponding sequence thereto, is usually divided at or in the GACregion and, in certain polynucleotide constructs, in particularribozymes, and occurs in two separate domains, the “recognition arms.”

FIG. 2 shows the sequence of an antisense deoxyoligonucleotide againsthuman VR1 corresponding in position on the mRNA to oligo V15 in FIG. 1.With regard to type and general content, subtypes or sequences (a)-(k)correspond to that already described in relation to FIG. 1.

FIG. 3 shows a list of general nucleotide sequences starting from anantisense oligodeoxynucleotide sequence against VR1 mRNA from the rat,here frequently designated oligo V30, oligonucleotide no. 30 or V30. Thetype and general content of the subtypes correspond to that alreadydescribed in relation to FIG. 1.

FIG. 4 shows the sequence of an antisense deoxyoligonucleotide againsthuman VR1 corresponding in position on the mRNA to oligo V30 in FIG. 3.With regard to type and general content, subtypes (a)-(q) correspond tothat already described in relation to FIG. 1.

FIG. 5 lists general nucleotide sequences starting from an antisenseoligodeoxynucleotide sequence against VR1 mRNA from the rat, herefrequently designated oligo V32, oligonucleotide no. 32 or V32. The typeand general content of the subtypes correspond to that already describedin relation to FIG. 1.

FIG. 6 shows the sequence of an antisense deoxyoligonucleotide againsthuman VR1 corresponding in position on the mRNA to oligo V32 in FIG. 5.With regard to type and general content, subtypes (a)-(q) correspond tothat already described in relation to FIG. 1.

FIG. 7 lists general nucleotide sequences starting from an antisenseoligodeoxynucleotide sequence against VR1 mRNA from the rat, herefrequently designated oligo V26, oligonucleotide no. 26 or V26. The typeand general content of the subtypes correspond to that already describedin relation to FIG. 1.

FIG. 8 shows the sequence of an antisense deoxyoligonucleotide againsthuman VR1 corresponding in position on the mRNA to oligo V26 in FIG. 7.With regard to type and general content, subtypes (a)-(q) correspond tothat already described in relation to FIG. 1.

FIG. 9 lists general nucleotide sequences starting from an antisenseoligodeoxynucleotide sequence against VR1 mRNA from the rat, herefrequently designated oligo V2, oligonucleotide no. 2 or V2. The typeand general content of the subtypes correspond to that already describedin relation to FIG. 1.

FIG. 10 shows the sequence of an antisense deoxyoligonucleotide againsthuman VR1 corresponding in position on the mRNA to oligo V2 in FIG. 9.With regard to type and general content, subtypes (a)-(k) correspond tothat already described in relation to FIG. 1.

FIG. 11 lists general nucleotide sequences starting from an antisenseoligodeoxynucleotide sequence against VR1 mRNA from the rat, herefrequently designated oligo V16, oligonucleotide no. 16 or V16. The typeand general content of the subtypes correspond to that already describedin relation to FIG. 1.

FIG. 12 shows the sequence of an antisense deoxyoligonucleotide againsthuman VR1 corresponding in position on the mRNA to oligo V16 in FIG. 11.With regard to type and general content, subtypes (a)-(q) correspond tothat already described in relation to FIG. 1.

FIG. 13 lists general nucleotide sequences starting from an antisenseoligodeoxynucleotide sequence against VR1 mRNA from the rat, herefrequently designated oligo V28, oligonucleotide no. 28 or V28. The typeand general content of the subtypes correspond to that already describedin relation to FIG. 1.

FIG. 14 shows the sequence of an antisense deoxyoligonucleotide againsthuman VR1 corresponding in position on the mRNA to oligo V28 in FIG. 13.With regard to type and general content, subtypes (a)-(k) correspond tothat already described in relation to FIG. 1.

FIG. 15 lists general nucleotide sequences starting from an antisenseoligodeoxynucleotide sequence against VR1 mRNA from the rat, herefrequently designated oligo V4, oligonucleotide no. 4 or V4. The typeand general content of the subtypes correspond to that already describedin relation to FIG. 1.

FIG. 16 shows the sequence of an antisense deoxyoligonucleotide againsthuman VR1 corresponding in position on the mRNA to oligo V4 in FIG. 15.With regard to type and general content, subtypes (a)-(k) correspond tothat already described in relation to FIG. 1.

FIG. 17 shows the result of messenger walk screening. In each trackthere can be seen, in addition to the upper band of the uncut substrate,the two product bands of the cut mRNA together with several non-specificbands. The figure shows the VR1 mRNA after degradation by RNase H in thepresence in each case of one of 33 antisense oligonucleotides (oligo V1to oligo V33). In each track there can be seen, in addition to the upperband of the uncut substrate, the two product bands of the cut mRNAtogether with several non-specific bands. Track 1: VR1 mRNA, tracks2-34: RNase H assay with antisense oligodeoxynucleotides against the 33GUC sites of VR1 mRNA (oligo V1 to oligo V33).

FIG. 18 shows quantitative evaluation of messenger walk screening. FIG.18 is a plot of the percentage of the uncut mRNA after the RNase H assaywith the individual ODNs. Each value is the mean of at least twoexperiments, such that the standard deviation does not ever exceed 10%.The antisense oligodeoxynucleotides against the 15th and 30th GUC sitesbind most efficiently to the VR1 mRNA, such that the latter isrespectively 88±4 and 97±1% degraded by the RNase H (oligo V15 and oligoV30).

FIG. 19 is an image of a gel after RNase H assay with oligonucleotidesV15, V15ctrl. (mismatch), V30 and V30ctrl. (mismatch). The Figure showsVR1 mRNA (track 1) and RNase H assay with oligodeoxynucleotides V15,V15ctrl., V30 and V30ctrl. (tracks 2-5).

FIG. 20 shows the quantitative evaluation of cleavage of mRNA byribozymes and DNA enzymes under “single turnover” conditions.

FIG. 21 shows the kinetics of VR1 mRNA cleavage by ribozymes and DNAenzymes under “single turnover” conditions.

FIG. 22 shows the kinetics of VR1 mRNA cleavage by ribozymes and DNAenzymes under “multiple turnover” conditions.

FIG. 23 shows an estimation of tactile allodynia during treatment byVR1-antisense (AS) oligodeoxynucleotides and mismatch (MS)oligodeoxynucleotides (V15 and V15ctrl.).

FIG. 24 is a general diagram of a “hammerhead” ribozyme with the“recognition arms” helix I and helix III, into which the helices I andIII according to subtypes (o)-(q) in one of FIG. 1, 3, 4, 5, 6, 7, 8, 9,11, 12, 13 or 15 are inserted, in order to obtain the inventivehammerhead ribozymes (see description relating to FIG. 1). The fragmenthelix I here replaces in each case in one of FIG. 1, 3, 4, 5, 6, 7, 8,9, 11, 12, 13 or 15 the desired nucleotides in helix I according to FIG.24 in such a manner that the first nucleotide on the 3′ end of helix Iin each case in one of FIG. 1, 3, 4, 5, 6, 7, 8, 9, 11, 12, 13 or 15replaces the first desired nucleotide “N” on the 3′ end of helix I ofFIG. 24 and the following desired nucleotides “N” in helix I, FIG. 24towards the 5′ end are replaced by the nucleotides which are shown inone of sequences (o) to (q) of helix I in each case in one of FIG. 1, 3,4, 5, 6, 7, 8, 9, 11, 12, 13 or 15. The nucleotides “A” and “C” on the5′ end of helix III in one of FIG. 1, 3, 4, 5, 6, 7, 8, 9, 11, 12, 13 or15 in each case replace the nucleotides “A” and “C” in helix III in FIG.24 and the following desired nucleotides “N” in helix III, FIG. 24 arereplaced in the 5′ end direction by the nucleotides which are shown inone of sequences (o)-(q), helix III, in each case in one of FIG. 1, 3,4, 5, 6, 7, 8, 9, 11, 12, 13 or 15.

FIG. 25 shows a specific example of the preparation of the (particularlypreferred) “hammerhead” ribozyme V16 (7/7) according to FIG. 24 and FIG.11. The designation ribozyme V16 (7/7) here means that the enzyme isoriented towards the GUC site of oligo V16 and contains 7 nucleotides ineach of the “recognition arms” (helix I and helix III), in this caseaccording to helix I and helix III of sequence (o) in FIG. 11. The sameapplies to all ribozymes according to sequences (o to q) in each case inone of FIG. 1, 3, 4, 5, 6, 7, 8, 9, 11, 12, 13 or 15.

FIG. 26 is a diagram of a type “10-23” DNA enzyme according to Santoroet al., 1997, FIG. 2, p. 4264; the upper strand marked with an arrow isthe RNA strand to be cleaved, the arrow showing the cleavage site, whilethe lower strand is a representation of the DNA enzyme. With regard tothe present application, in the upper strand the “Y”=“U” and the“R”=“G”, a “C” being located 3′-wards from “Y”. The cleavage site on theupper strand is thus a GUC site (see above). Correspondingly, “R” in thelower strand=“A”, a “G” correspondingly being located 5′-wards from “R”in the lower strand. This is followed 5′-wards by the furthernucleotides from Fragment I according to sequences (l) to (n) in eachcase in one of FIG. 1, 3, 4, 5, 6, 7, 8, 9, 11, 12, 13 or 15, i.e. 5further nucleotides in sequence l, 6 further nucleotides in sequence mand 7 further nucleotides in sequence n. In Fragment III according toFIG. 25, the second with the RNA base-paired fragment, the unpaired “A”on Fragment III is then directly followed from the 5′ direction 3′-wardsby the nucleotides from Fragment III according to sequences (l) to (n)in each case in one of FIG. 1, 3, 4, 5, 6, 7, 8, 9, 11, 12, 13 or 15,i.e. 7 further nucleotides in sequence l, 8 further nucleotides insequence m and 9 further nucleotides in sequence n. Fragment III andFragment I are the “recognition arms” of the DNA enzyme (see Example 3).The type “10-23” DNA enzyme for sequence (n) according to FIG. 1 wouldthus have the following sequence, wherein the underlined fragment wouldbe base-paired with the RNA:

(SEQ ID NO: 249) ATGTCATGA(=R)-GGCTAGCTACAACGA-GGTTAGGGG

This DNA enzyme would be named V15 (9/9), wherein the name indicatesthat the enzyme is oriented towards the GUC site of oligo V15 and the“recognition arms” in each case contain 9 nucleotides (Fragment I andIII), for example according to Fragment I and Fragment III of sequence(n) in FIG. 1. The same applies to all DNA enzymes according tosequences (l) to (n) in each case in one of FIG. 1, 3, 4, 5, 6, 7, 8, 9,11, 12, 13 or 15.

FIG. 27 is a schematic diagram of a “locked nucleic acid” (LNA).

EXAMPLES Example 1 Identification of Generally Suitable RestrictionSites

The first step in the antisense and ribozyme strategy is to identifyaccessible sites on the mRNA for binding oligonucleotides, in particularribozymes. To this end, the VR1 mRNA had to be investigated for suchrestriction sites. Analysis of the VR1 mRNA revealed the followingpotential recognition sites for ribozymes in the coding domain:

33×GT(U)C sequences,

28×GT(U)T sequences, and

12×GT(U)A sequences.

In order to determine the accessible sites on the VR1 mRNA, in a firststep, three independent nucleotide mixtures with the following sequencewere synthesized:

-   -   Mixture 1: NNNAACNNN “GUU library,”    -   Mixture 2: NNNCACNNN “GUA library,” and    -   Mixture 3: NNNGACNNN “GUC library.”

These were used consecutively in an RNase H experiment and it was foundthat appreciable degradation of the VR1 mRNA was observed only with theGUC library. Thus, of the potential target sequences for ribozymes, the33 GUC sites in the VR1 mRNA are the most readily accessible and theywere used for further analyses.

Example 2 Identification of the Most Effective AntisenseOligodeoxynucleotides

Messenger Walk Screening

In order to identify mRNA domains which are accessible to antisenseoligodeoxynucleotides, the mRNA was systematically screened with ODNs inan RNase H assay (messenger walk screening). The ODNs were 18nucleotides in length and contained a central GAC sequence, which isreverse complementary to GUC sequences in the mRNA. This triplet wasselected as the target as it provided good results and may be used in asecond step to develop hammerhead ribozymes and DNA enzymes. In total,33 ODNs, designated V1 to V33, were tested against all the GUC sites ofthe VR1 mRNA. The ODNs were systematically screened for theirsuitability by the addition in each case of one ODN and RNase H to themRNA. RNase H cuts formed DNA/RNA duplexes wherever an oligonucleotidecan bind to the mRNA (FIG. 17).

In Vitro Transcription of VR1 mRNA

First of all, the cDNA of the vanilloid receptor was cloned into thevector pcDNA3.1 (+) from Invitrogen. Then, in vitro transcription of themRNA was performed using the RiboMAX Large Scale RNA ProductionSystem—T7 from Promega in accordance with the manufacturer'sinstructions.

RNase H Assay

An RNase H assay was performed to test whether an antisenseoligodeoxynucleotide had bound to the mRNA. To this end, the VR1 mRNA(100 mM) was incubated with a five-fold excess of the ODNs in a totalvolume of 10 μl in 40 mM tris/HCl pH 7.2, 4 mM MgCl₂, 1 mM DTT and 150mM NaCl for 7.5 minutes at 37° C. in the presence of 0.4 unit of RNase H(from Promega). The reactions were terminated by addition of EDTA (65 mMfinal concentration). The samples were separated on a 1.5% agarose geland stained with ethidium bromide (1 μg/ml) for 20 minutes. The gelswere photographed with the Gel Doc 2000 Gel Documentation System fromBiorad and evaluated with Quantity One software.

FIG. 17 shows the result of messenger walk screening. In each trackthere can be seen, in addition to the upper band of the uncut substrate,the two product bands of the cut mRNA together with several non-specificbands.

Quantification of RNA degradation revealed that the most effectiveantisense oligonucleotide (oligo no. 30 (V30)) was able specifically tocut/cleave more than 90% of the VR1 mRNA when used in a five-fold excessrelative to the target mRNA (FIG. 18).

The intensities of the individual bands were evaluated. FIG. 18 is aplot of the percentage of the uncut mRNA for the individual ODNs afterthe RNase H assay. The antisense oligodeoxynucleotides against the 15thand 30th GUC sites (oligo V15 and oligo V30) bind most efficiently tothe VR1 mRNA, such that the latter is respectively 88±4 and 97±1%degraded by the RNase H.

The sequences of the antisense oligodeoxynucleotides most effective inthis test are shown in FIGS. 1, 3, 5, 7, 9, 11, 13 and 15, wherein interalia preferential attention was paid to those designated oligo V15(FIG. 1) and oligo V30 (FIG. 3).

Oligodeoxynucleotides in which every fifth and six base (or in the eventthat these are identical, two adjacent bases) are swapped weresynthesized and used in the following experiments as mismatch controlsfor these antisense oligodeoxynucleotides. The sequences of the control(mismatch) oligodeoxynucleotides are:

Oligo V15ctrl.: CAT GCT ATG AGC GTT GAG (SEQ ID NO: 250) Oligo V30ctrl.:ATC TGT TTG AGC GTC TAC (SEQ ID NO: 251)

The RNase H assay was performed with the oligonucleotides V15, V15ctrl.,V30 and V30ctrl. for control purposes (see FIG. 19). As anticipated, theRNA is degraded only with the antisense ODNs, but not with the mismatchcontrols, as the latter do not bind to the mRNA.

SUMMARY

By using the RNase H assay with antisense oligodeoxynucleotides againstall the GUC triplets of the VR1 mRNA, it was possible to identifyoligodeoxynucleotides against the GUC triplets (2, 4, 15, 16, 26, 28, 30and 32), in particular the 15th and 30th which were the ODNs with thebest binding properties. These oligodeoxynucleotides and the twomismatch controls are thus available for testing in an animal model andfor other uses.

The human sequences according to FIGS. 2, 4, 6, 8, 10, 12, 14, 16, whichcorrespond in position to those found in the rat sequences, are ofparticular interest. Rat and human mRNAs are highly homologous (probablyalso in terms of folding) and it is thus clear that restriction sitesidentified as readily accessible on rat mRNA are also of interest forhumans. Particularly preferred sequences here are those which alsoexhibit the GUC triplet, FIGS. 4, 6, 8 and 12, and, due to the locationsimilar to that in rats, also those corresponding to V15 and V30according to FIGS. 2 and 4.

Example 3 Ribozymes and DNA Enzymes

On the basis of the identified most effective binding sites,corresponding ribozymes and DNA enzymes were also investigated.

“Hammerhead” ribozymes and type “10-23” DNA enzymes (Santoro et al.,1997) were constructed against the mRNA sites which were accessible toODNs. The length of the “recognition arms” was 7 or 9 nucleotides oneach side. Quantitative evaluation of mRNA cleavage/restriction under“single turnover” conditions (10-fold excess of ribozymes and DNAenzymes) revealed after 20 minutes at 37° C. that ribozymes with shorter“recognition arms” (helix I and helix III) are more active, while inturn in DNA enzymes, those with longer “arms” (Fragment I and FragmentIII) are more active (FIG. 20). FIG. 24 is a schematic representation ofa ribozyme with the helices I and III, while FIG. 25 shows a specificexample. This may be seen for a 10-23 DNA enzyme (5′-end (Fragment I)and 3′-end (Fragment III) from the catalytic motif) in Santoro et al.(1997, p. 4264, FIG. 2) (see also FIG. 26) with the description of theFigures).

Experiments with ribozymes and DNA enzymes were carried out in 50 mMtris/HCl, pH 7.5 and 10 mM MgCl₂ at 37° C. In the “single turnover”experiments, the ribozymes and DNA enzymes were used in a 10-foldexcess. In “multiple turnover” experiments, the substrate mRNA was usedin a 10-fold excess.

“Single Turnover” Kinetics

A kinetic analysis under “single turnover” conditions was carried outfor the two most effective ribozymes and DNA enzymes (FIG. 21). The dataare shown in Table 1. DNA enzyme V15 (9/9) (see description of FIG. 26),which cuts the mRNA with biphasic kinetics, has the highest rate (rateconstant), followed by ribozyme V16 (7/7) (see FIG. 25), DNA enzyme V30(9/9) and the slowest ribozyme V15 (7/7). The designation ribozyme V15(7/7), for example, here means that the enzyme is oriented towards theGUC site of oligo V15 and contains 7 nucleotides in each of the“recognition arms” (helix I and helix III), for example according toFragment I and Fragment III of subtype (l) in FIG. 1.

TABLE 1 Kinetics data for ribozymes and DNA enzymes against VR1 mRNAunder “single turnover” conditions. k₁ k₂ A₁ [min⁻¹] A₂ [min⁻¹] A_(∞)DNAzyme V15 (9/9) 0.43 ± 0.05 2.3 ± 0.5 0.34 ± 0.04 0.07 ± 0.01 0.21 ±0.03 DNAzyme V30 (9/9) 0.90 ± 0.02 0.042 ± 0.002 — — 0.08 ± 0.02 RiboV15 (7/7) 0.51 ± 0.09 0.023 ± 0.007 — — 0.49 ± 0.09 Ribo V16 (7/7) 0.58± 0.02 0.077 ± 0.008 — — 0.34 ± 0.03

“Multiple Turnover” Kinetics

FIG. 22 shows the cleavage of the mRNA under “multiple turnover”conditions (10-fold substrate excess). Again DNA enzyme V15 (9/9) has ahigher apparent rate (rate constant) (by a factor of 3.4) than ribozymeV16 (7/7) (Table 2).

TABLE 2 Kinetics data for ribozymes and DNA enzymes against VR1 mRNAunder “multiple turnover” conditions k [min⁻¹] DNAzyme V15 (9/9) (6.5 ±0.6) * 10⁻³ Ribo V16 (7/7) (1.9 ± 0.2) * 10⁻³

Example 4 In Vivo Experiments

Spinal nerve ligatures were placed as described by Kim & Chung (1992) onthe left L5/L6 spinal nerves of 20 male Sprague-Dawley rats. At the sametime, spinal catheters were implanted as described by Pogatzki et al.(2000). Four to six days after the operation, the tactile thresholdbaseline (withdrawal thresholds) was measured on the ipsilateral andcontralateral hind paw using an electronic von Frey anaesthesiometer(IITC Life Science, USA). Correct positioning of the spinal catheter wasconfirmed by administering lidocaine (10 μl, 2%), which resulted intransient paralysis of both hind limbs. After the test and measurementof the baseline, 45 μg of VR-1 antisense oligonucleotides (AS, n=10) ormismatch oligonucleotides (MS, n=10) in 0.9% NaCl were in each casegiven once on the first day and b.i.d. on the following 4 days. Thetactile withdrawal thresholds were measured 30 minutes after the firstdaily administration of oligo. The results are stated as a percentage ofthe maximum possible effect (% MPE) on the ipsilateral side, the baseline being taken as 0% and the withdrawal threshold of a control groupas 100% MPE. The antisense oligo used was V15 (FIG. 1, subtype k), whilethe mismatch oligo was V15ctrl., as already described above.

Treating mononeuropathic rats with antisense, but not with mismatch,oligodeoxynucleotides brought about a reduction in tactile allodyniabeginning on the third day of treatment, with a plateau being reached ondays 4 and 5 of treatment. There was no effect on the withdrawalthresholds of the contralateral hind paw.

Example 5 “Locked Nucleotides”/Oligonucleotides Protected fromDegradation and Oligonucleotide Constructs

Various different oligonucleotides according to the invention wereproduced, in particular according to subgroup (k) of FIG. 1 and, in somecases, also FIG. 3. Most of these were LNA constructs which wereobtained from PROLIGO, in Boulder, Colo., and in which LNAs were locatedat various sites (see Table 3). An unmodified oligonucleotide accordingto subgroup (k) of FIG. 1 was also synthesized and a phosphorothioatecorresponding in terms of base sequence was obtained from MWG Biotech AGin Ebersberg, Germany.

TABLE 3 List of oligonucleotides used % mRNA % LNA DNA Name Sequencecleavage content gap DNA 1 catgtcatgacggttagg  90 ± 1 0 — PSCATGTCATGACGGTTAGG  71 ± 7 0 — mixed LNA 1 catgTcaTgacggTtagg*  12 ± 216 5 LNA 2 CatgTcaTgacggTtagg  11 ± 9 22 5 LNA 3 catgTcaTgacggTTagg 4 ±1 22 5 LNA 4 catgTcaTgaCggTtagG 5 ± 9 27 2 LNA 5 CaTgTcaTgaCggTTagG 2 ±3 44 2 LNA 6 catgTcatGacggTtagg  12 ± 2 16 4 LNA 7 CatgTcatGacggTtagg8 ± 4 22 4 LNA 8 catgTcatGacggTtagG 9 ± 1 22 4 LNA 9 CatgTcatGacggTtagG7 ± 2 27 4 LNA 10 CatgTcaTgaCggTtagG 7 ± 1 33 2 LNA 11CaTgTcatgacggTTagG  81 ± 5 33 8 gaps LNA 12 CatgTcaTgacggTtagG 6 ± 4 275 LNA 13 CatgTcAtgacggTtagG 49 ± 12 27 6 LNA 14 CatgTCatgacggTtagG  83 ±6 27 7 LNA 15 CatgTcatgacggTtagG  91 ± 2 22 8 end block oligonucleotidesLNA 16 CATGTcatgacggTTAGG  85 ± 6 55 8 LNA 17 CATGtcatgacggtTAGG  94 ± 344 10 LNA 18 CATgtcatgacggttAGG  93 ± 2 33 12 LNA 19 CatgtcatgacggttaGG87 ± 12 22 14 LNA 20 CatgtcatgacggttagG  85 ± 6 11 16 control sequencesDNA 2 atcttgttgacggtctca  97 ± 2 0 — LNA 21 AtctTgttGacggTctcA 0 ± 0 274 LNA 22 AtctTgttgacggTctcA  95 ± 3 22 8 LNA 23 ATCTTgttgacggTCTCA  97 ±1 55 8 *Note: Lower case = DNA monomers; italic and underlined =phosphorothioates; bold characters = LNA monomers.

Various tests were carried out with these oligonucleotides:

a) Firstly, the percentage of RNA cleavage of VR1 by RNase H initiatedby the oligonucleotide was investigated, the test conditionssubstantially matching those stated in Example 2.

The results are shown in Table 3. It was found that oligonucleotideswith LNA only exhibited cleavage comparable with the nativeoligonucleotide if at least 6, or especially at least 8 contiguousnucleotides were not LNAs.

b) The melting temperature of the LNA/RNA:DNA hybrids were then measuredby standard methods (Table 4). Surprisingly, the LNAs did not exhibit araised melting temperature in comparison with the nativeoligonucleotides and the phosphorothioates. This is very favorable forstability.

TABLE 4 Melting temperature T_(m) of LNA/DNA:RNA hybrids T_(m)Oligonucleotide No. of LNAs ° C. DNA 1 0 58 PS 0 49 LNA 20 2 61 LNA 19 466 LNA 18 6 73 LNA 17 3 79 LNA 16 10 ~85

c) The kinetics of RNase H cleavage were then investigated underidentical conditions to those above, except that equimolar quantities ofRNA and antisense oligonucleotide (100 nM each) were used. The resultsare shown in Table 5. Surprisingly, the oligonucleotide with LNAexhibited a distinct increase in activity in comparison with the nativeoligonucleotides and phosphorothioates.

TABLE 5 Rate constants for RNase H cleavage of “full-length” VR1 mRNA byantisense oligonucleotides. Oligonucleotide k [min⁻¹] DNA 1 0.17 ± 0.01LNA 17 1.1 ± 0.6 PS 0.07 + 0.01

d) Finally, the half-life of the radioactively labelled oligonucleotideswith LNA of the native oligonucleotide and of the phosphorothioate wasdetermined at 37° C. in human serum over a period of up to 2 days. Theresults are shown in Table 6. While the half-life of the native DNA is1.5 h and that of the phosphorothioate is 10 h, the half-life ofnucleotides with LNA, on the 3 or 4 ends, were significantly long with at_(1/2) of approximately 17 h.

TABLE 6 Half-life of native, phosphorothioate and end block LNA/DNAoligonucleotides in human serum. Oligonucleotide nt end block t_(1/2)[h] DNA 1 0  1.5 ± 0.3 PS 0 10 ± 2 LNA 20 1  4 ± 2 LNA 19 2   6 ± #?#LNA 18 3 17 + 2 LNA 17 4 15 ± 1 LNA 16 5 15 + 2

The best restriction properties were thus achieved by the nucleotideswith LNAs which had approximately 8 contiguous nucleotides without LNAsand had 3 or 4 LNAs on the 3′ and 5′ ends.

The foregoing description and examples have been set forth merely toillustrate the invention and are not intended to be limiting. Sincemodifications of the described embodiments incorporating the spirit andsubstance of the invention may occur to persons skilled in the art, theinvention should be construed broadly to include all variations fallingwithin the scope of the appended claims and equivalents thereof.

BIBLIOGRAPHIC REFERENCES

-   Caterina, M. J.; Schumacher, M. A.; Tominaga, T. A.; Rosen, T. A.;    Levine, J. D.; Julius, D. (1997) The capsaicin receptor: a    heat-activated ion channel in the pain pathway. Nature 389, 816-824.-   Caterina, M. J.; Leffler, A.; Malmberg, A. B.; Martin, W. J.;    Trafton, J.; Petersen-Zeitz, K. R.; Koltzenburg, M; Basbaum, A. L;    Julius, D. (2000) Impaired nociception and pain Sensation in mice    lacking the capsaicin receptor. Science 288, 306-313.-   Davis, J. B.; Gray, J.; Gunthorpe, M. J.; Hatcher, J. P.; Davey, P.    T.; Overend, P.; Harries, M. H.; Latcham, J.; Clapham, C.; Atkinson,    K.; Hughes, S. A.; Rance, K.; Grau, E.; Harper, A. J.; Pugh, P. L.;    Rogers, D. C.; Bingham, S.; Randall, A.; Sheardown, S. A. (2000)    Vanilloid receptor-1 is essential for inflammatory thermal    hyperalgesia. Nature 405, 183-187.-   Kim, S. H.; Chung, J. M. (1992) An experimental model for peripheral    mononeuropathy produced by segmental spinal nerve ligation in the    rat. Pain 50, 355-363.-   Pogatzki, E. M.; Zahn, P. K.; Brennan, T. J. (2000) Lumbar    catheterization of the subarachnoid space with a 32-gauge    polyurethane catheter in the rat. Eur. J. Pain 4, 111-113.-   Porreca, F.; Lai, J.; Bian, D.; Wegert, S.; Ossipov, M. H.;    Eglen, R. M.; Kassotakis, L.; Novakovic, S.; Rabert, D. K.;    Sangameswaran, L.; Hunter, J. C. (1999) A comparison of the    potential role of the tetrodotoxin-insensitive sodium channels,    PN3/SNS and NaN/SNS2, in rat models of chronic pain. Proc. Natl.    Acad. Sei. USA 96, 7640-7644.-   Santoro, S. W.; Joyce, G. F. (1997) A general purpose RNA-cleaving    DNA enzyme. Proc. Natl. Acad. Sci. USA 94, 4262-4266.-   Vaish, N. K. et al. (1998), Nucl. Acid Res. 26, 5237-5242.

1. An oligonucleotide comprising the sequence according to one of SEQ IDNOs 19-27, SEQ ID NOs 30-38, SEQ ID NOs 47-55, SEQ ID NOs 64-72, SEQ IDNOs 81-89, SEQ ID NOs 98-106, SEQ ID NOs 115-123, SEQ ID NOs 132-140,SEQ ID NOs 149-157, SEQ ID NOs 160-168, SEQ ID NOs 178-186, SEQ ID NOs195-203, SEQ ID NOs 212-220, SEQ ID NOs 223-231 or SEQ ID NOs 240-248,wherein each of SEQ ID NOs 19-27 comprises a sequence domain of SEQ IDNO 18, each of SEQ ID NOs 30-38 comprises a sequence domain of SEQ ID NO29, each of SEQ ID NOs 47-55 comprises a sequence domain of SEQ ID NO46, each of SEQ ID NOs 64-72 comprises a sequence domain of SEQ ID NO63, each of SEQ ID NOs 81-89 comprises a sequence domain of SEQ ID NO80, each of SEQ ID NOs 98-106 comprises a sequence domain of SEQ ID NO97, each of SEQ ID NOs 115-123 comprises a sequence domain of SEQ ID NO114, each of SEQ ID NOs 132-140 comprises a sequence domain of SEQ ID NO131, each of SEQ ID NOs 149-157 comprises a sequence domain of SEQ ID NO148, each of SEQ ID NOs 160-168 comprises a sequence domain of SEQ ID NO159, each of SEQ ID NOs 178-186 comprises a sequence domain of SEQ ID NO177, each of SEQ ID NOs 195-203 comprises a sequence domain of SEQ ID NO194, each of SEQ ID NOs 212-220 comprises a sequence domain of SEQ ID NO211, each of SEQ ID NOs 223-231 comprises a sequence domain of SEQ ID NO222, or each of SEQ ID NOs 240-248 comprises a sequence domain of SEQ IDNO
 239. 2. An oligonucleotide according to claim 1, comprising (1) abase sequence according to SEQ ID NOs 28, 56, 73, 90, 107, 124, 141,158, 169, 187, 204, 221, 232, or 249, or (2) a sequence differing from(1) by at most two different bases not located in the sequence accordingto SEQ ID NO 18, 46, 63, 80, 97, 114, 131, 148, 159, 177, 194, 211, 222,or 239, respectively.
 3. An anti-sense oligonucleotide 15 to 30nucleotides in length and comprising (1) the sequence according to oneof SEQ ID NOs 19-27, SEQ ID NOs 47-55, SEQ ID NOs 64-72, SEQ ID NOs81-89, SEQ ID NOs 98-106, SEQ ID NOs 115-123, SEQ ID NOs 132-140, SEQ IDNOs 149-157, SEQ ID NOs 160-168, SEQ ID NOs 178-186, SEQ ID NOs 195-203,SEQ ID NOs 212-220, SEQ ID NOs 223-231 or SEQ ID NOs 240-248, or (2) asequence differing from (1) by one different base not located in thesequence according to SEQ ID NO 18, 46, 63, 80, 97, 114, 131, 148, 159,177, 194, 211, 222 or 239, respectively.
 4. An anti-senseoligonucleotide according to claim 2, wherein the oligonucleotide is SEQID NO 28, 56, 73, 90, 107, 124, 141, 158, 169, 187, 204, 221, 232, or249.
 5. An anti-sense oligonucleotide selected from the group consistingof SEQ ID NOs 12-17, SEQ ID NOs 18-28, SEQ ID NOs 29-45, SEQ ID NOs46-62, SEQ ID NOs 131-147, SEQ ID NOs 148-158, SEQ ID NOs 159-176, SEQID NOs 177-193, SEQ ID NOs 222-238, and SEQ ID NOs 239-249.
 6. Anoligonucleotide according to claim 5, wherein the oligonucleotide isselected from the group consisting of SEQ ID NOs 12-17, SEQ ID NOs18-28, SEQ ID NOs 29-45, SEQ ID NOs 46-62, SEQ ID NOs 159-176 and SEQ IDNOs 177-193.
 7. An oligonucleotide according to claim 5, wherein theoligonucleotide is selected from the group consisting of SEQ ID NOs12-17, SEQ ID NOs 29-45 and SEQ ID NOs 159-176.
 8. An oligonucleotideaccording to claim 5, wherein the oligonucleotide is selected from thegroup consisting of SEQ ID NOs 12-17 and SEQ ID NOs 29-45.
 9. Anoligonucleotide according to claim 1, wherein at least one of thenucleotides is a “locked nucleic acid” (LNA), and wherein more than 6contiguous nucleotides in the oligonucleotide are not LNA's, and whereinthe more than 6 contiguous nucleotides that are not LNAs are in thesequence domain of SEQ ID NO 18, 29, 46, 63, 80, 97, 114, 131, 148, 159,177, 194, 211, 222 or
 239. 10. A polynucleotide construct comprising atleast one oligonucleotide according to claim
 1. 11. A polynucleotideconstruct comprising, in two separate domains, Fragment I and FragmentIII according to one of SEQ ID NOs 12-14, SEQ ID NOs 40-42, SEQ ID NOs57-59, SEQ ID NOs 74-76, SEQ ID NOs 91-93, SEQ ID NOs 108-110, SEQ IDNOs 125-127, SEQ ID NOs 1452-144, SEQ ID NOs 170, 172 and 173, SEQ IDNOs 188-190, SEQ ID NOs 205-207, or SEQ ID NOs 233-235, or helix I andhelix III according to one of SEQ ID NOs 15-17, SEQ ID NOs 43-45, SEQ IDNOs 60-62, SEQ ID NOs 77-79, SEQ ID NOs 94-96, SEQ ID NOs 11-113, SEQ IDNOs 128-130, SEQ ID NOs 145-147, SEQ ID NOs 174-176, SEQ ID NOs 191-193,SEQ ID NOs 208-210 or SEQ ID NOs 236-238.
 12. A ribozyme comprising anoligonucleotide of claim 1, comprising helix I and helix III accordingto one of SEQ ID NOs 15-17, SEQ ID NOs 43-45, SEQ ID NOs 60-62, SEQ IDNOs 77-79, SEQ ID NOs 94-96, SEQ ID NOs 128-130, SEQ ID NOs 174-176 orSEQ ID NOs 191-193.
 13. A ribozyme according to claim 12, comprisinghelix I and helix III according to SEQ ID NO 15, 43, 60, 77, 94, 128,174 or
 191. 14. A ribozyme according to claim 12, comprising helix I andhelix III according to one of SEQ ID NOs 15-17, SEQ ID NOs 43-45 or SEQID NOs 174-176.
 15. A ribozyme according to claim 12, comprising helix Iand helix III according to one of SEQ ID NOs 60-62, SEQ ID NOs 94-96,SEQ ID NOs 128-130 or SEQ ID NOs 191-193.
 16. A DNA enzyme comprising anoligonucleotide of claim 1, comprising Fragment I and Fragment IIIaccording to one of SEQ ID NOs 12-14, SEQ ID NOs 40-42, SEQ ID NOs57-59, SEQ ID NOs 74-76, SEQ ID NOs 91-93, SEQ ID NOs 108-110, SEQ IDNOs 125-127, SEQ ID NOs 1452-144, SEQ ID NOs 170, 172 and 173, SEQ IDNOs 188-190 or SEQ ID NOs 205-207.
 17. A DNA enzyme according to claim16, comprising Fragment I and Fragment III according to one of SEQ IDNOs 12-14, SEQ ID NOs 40-42, SEQ ID NOs 108-110 or SEQ ID NOs 170, 172and
 173. 18. A DNA enzyme according to claim 16, comprising Fragment Iand Fragment III according to one of SEQ ID NOs 57-59, SEQ ID NOs 91-93,SEQ ID NOs 125-127 or SEQ ID NOs 188-190.
 19. A DNA enzyme according toclaim 16, comprising Fragment I and Fragment III according to SEQ ID NO14, 42, 59, 76, 93, 110, 127, 144, 173, 190 or
 207. 20. A method for thetreatment of pain, comprising administering an effective amount of apharmaceutical composition comprising at least one oligonucleotidecomprising the sequence according to one of SEQ ID NOs 2-10, SEQ ID NOs19-27, SEQ ID NOs 30-38, SEQ ID NOs 47-55, SEQ ID NOs 64-72, SEQ ID NOs81-89, SEQ ID NOs 98-106, SEQ ID NOs 115-123, SEQ ID NOs 132-140, SEQ IDNOs 149-157, SEQ ID NOs 160-168, SEQ ID NOs 178-186, SEQ ID NOs 195-203,SEQ ID NOs 212-220, SEQ ID NOs 223-231 or SEQ ID NOs 240-248, whereineach of SEQ ID NOs 2-10 comprises a sequence domain of SEQ ID NO 1, eachof SEQ ID NOs 19-27 comprises a sequence domain of SEQ ID NO 18, each ofSEQ ID NOs 30-38 comprises a sequence domain of SEQ ID NO 29, each ofSEQ ID NOs 47-55 comprises a sequence domain of SEQ ID NO 46, each ofSEQ ID NOs 64-72 comprises a sequence domain of SEQ ID NO 63, each ofSEQ ID NOs 81-89 comprises a sequence domain of SEQ ID NO 80, each ofSEQ ID NOs 98-106 comprises a sequence domain of SEQ ID NO 97, each ofSEQ ID NOs 115-123 comprises a sequence domain of SEQ ID NO 114, each ofSEQ ID NOs 132-140 comprises a sequence domain of SEQ ID NO 131, each ofSEQ ID NOs 149-157 comprises a sequence domain of SEQ ID NO 148, each ofSEQ ID NOs 160-168 comprises a sequence domain of SEQ ID NO 159, each ofSEQ ID NOs 178-186 comprises a sequence domain of SEQ ID NO 177, each ofSEQ ID NOs 195-203 comprises a sequence domain of SEQ ID NO 194, each ofSEQ ID NOs 212-220 comprises a sequence domain of SEQ ID NO 211, each ofSEQ ID NOs 223-231 comprises a sequence domain of SEQ ID NO 222, or eachof SEQ ID NOs 240-248 comprises a sequence domain of SEQ ID NO 239, anda pharmaceutically acceptable carrier, to a patient in need thereof. 21.A method according to claim 20, for the treatment of chronic painselected from the group consisting of tactile allodynia, thermallyinduced pain and inflammatory pain.
 22. A method for the treatment ofurinary incontinence, neurogenic bladder symptoms; pruritus; or tumors,comprising administering an effective amount of a pharmaceuticalcomposition comprising at least one oligonucleotide comprising thesequence according to one of SEQ ID NOs 2-10, SEQ ID NOs 19-27, SEQ IDNOs 30-38, SEQ ID NOs 47-55, SEQ ID NOs 64-72, SEQ ID NOs 81-89, SEQ IDNOs 98-106, SEQ ID NOs 115-123, SEQ ID NOs 132-140, SEQ ID NOs 149-157,SEQ ID NOs 160-168, SEQ ID NOs 178-186, SEQ ID NOs 195-203, SEQ ID NOs212-220, SEQ ID NOs 223-231 or SEQ ID NOs 240-248, wherein each of SEQID NOs 2-10 comprises a sequence domain of SEQ ID NO 1, each of SEQ IDNOs 19-27 comprises a sequence domain of SEQ ID NO 18, each of SEQ IDNOs 30-38 comprises a sequence domain of SEQ ID NO 29, each of SEQ IDNOs 47-55 comprises a sequence domain of SEQ ID NO 46, each of SEQ IDNOs 64-72 comprises a sequence domain of SEQ ID NO 63, each of SEQ IDNOs 81-89 comprises a sequence domain of SEQ ID NO 80, each of SEQ IDNOs 98-106 comprises a sequence domain of SEQ ID NO 97, each of SEQ IDNOs 115-123 comprises a sequence domain of SEQ ID NO 114, each of SEQ IDNOs 132-140 comprises a sequence domain of SEQ ID NO 131, each of SEQ IDNOs 149-157 comprises a sequence domain of SEQ ID NO 148, each of SEQ IDNOs 160-168 comprises a sequence domain of SEQ ID NO 159, each of SEQ IDNOs 178-186 comprises a sequence domain of SEQ ID NO 177, each of SEQ IDNOs 195-203 comprises a sequence domain of SEQ ID NO 194, each of SEQ IDNOs 212-220 comprises a sequence domain of SEQ ID NO 211, each of SEQ IDNOs 223-231 comprises a sequence domain of SEQ ID NO 222, or each of SEQID NOs 240-248 comprises a sequence domain of SEQ ID NO 239, and apharmaceutically acceptable carrier, to a patient in need thereof.
 23. Amethod for the treatment of vanilloid receptor subtype 1(VR1)-associated disease, comprising administering an effective amountof a pharmaceutical composition comprising at least one oligonucleotidecomprising the sequence according to one of SEQ ID NOs 2-10, SEQ ID NOs19-27, SEQ ID NOs 30-38, SEQ ID NOs 47-55, SEQ ID NOs 64-72, SEQ ID NOs81-89, SEQ ID NOs 98-106, SEQ ID NOs 115-123, SEQ ID NOs 132-140, SEQ IDNOs 149-157, SEQ ID NOs 160-168, SEQ ID NOs 178-186, SEQ ID NOs 195-203,SEQ ID NOs 212-220, SEQ ID NOs 223-231 or SEQ ID NOs 240-248, whereineach of SEQ ID NOs 2-10 comprises a sequence domain of SEQ ID NO 1, eachof SEQ ID NOs 19-27 comprises a sequence domain of SEQ ID NO 18, each ofSEQ ID NOs 30-38 comprises a sequence domain of SEQ ID NO 29, each ofSEQ ID NOs 47-55 comprises a sequence domain of SEQ ID NO 46, each ofSEQ ID NOs 64-72 comprises a sequence domain of SEQ ID NO 63, each ofSEQ ID NOs 81-89 comprises a sequence domain of SEQ ID NO 80, each ofSEQ ID NOs 98-106 comprises a sequence domain of SEQ ID NO 97, each ofSEQ ID NOs 115-123 comprises a sequence domain of SEQ ID NO 114, each ofSEQ ID NOs 132-140 comprises a sequence domain of SEQ ID NO 131, each ofSEQ ID NOs 149-157 comprises a sequence domain of SEQ ID NO 148, each ofSEQ ID NOs 160-168 comprises a sequence domain of SEQ ID NO 159, each ofSEQ ID NOs 178-186 comprises a sequence domain of SEQ ID NO 177, each ofSEQ ID NOs 195-203 comprises a sequence domain of SEQ ID NO 194, each ofSEQ ID NOs 212-220 comprises a sequence domain of SEQ ID NO 211, each ofSEQ ID NOs 223-231 comprises a sequence domain of SEQ ID NO 222, or eachof SEQ ID NOs 240-248 comprises a sequence domain of SEQ ID NO 239, anda pharmaceutically acceptable carrier, to a patient in need thereof. 24.A method according to claim 23, wherein the VR1 receptor-associateddisease is inflammation.
 25. A gene therapy method comprisingadministering to a patient in need thereof an effective amount of anoligonucleotide comprising the sequence according to one of SEQ ID NOs2-10, SEQ ID NOs 19-27, SEQ ID NOs 30-38, SEQ ID NOs 47-55, SEQ ID NOs64-72, SEQ ID NOs 81-89, SEQ ID NOs 98-106, SEQ ID NOs 115-123, SEQ IDNOs 132-140, SEQ ID NOs 149-157, SEQ ID NOs 160-168, SEQ ID NOs 178-186,SEQ ID NOs 195-203, SEQ ID NOs 212-220, SEQ ID NOs 223-231 or SEQ ID NOs240-248, wherein each of SEQ ID NOs 2-10 comprises a sequence domain ofSEQ ID NO 1, each of SEQ ID NOs 19-27 comprises a sequence domain of SEQID NO 18, each of SEQ ID NOs 30-38 comprises a sequence domain of SEQ IDNO 29, each of SEQ ID NOs 47-55 comprises a sequence domain of SEQ ID NO46, each of SEQ ID NOs 64-72 comprises a sequence domain of SEQ ID NO63, each of SEQ ID NOs 81-89 comprises a sequence domain of SEQ ID NO80, each of SEQ ID NOs 98-106 comprises a sequence domain of SEQ ID NO97, each of SEQ ID NOs 115-123 comprises a sequence domain of SEQ ID NO114, each of SEQ ID NOs 132-140 comprises a sequence domain of SEQ ID NO131, each of SEQ ID NOs 149-157 comprises a sequence domain of SEQ ID NO148, each of SEQ ID NOs 160-168 comprises a sequence domain of SEQ ID NO159, each of SEQ ID NOs 178-186 comprises a sequence domain of SEQ ID NO177, each of SEQ ID NOs 195-203 comprises a sequence domain of SEQ ID NO194, each of SEQ ID NOs 212-220 comprises a sequence domain of SEQ ID NO211, each of SEQ ID NOs 223-231 comprises a sequence domain of SEQ ID NO222, or each of SEQ ID NOs 240-248 comprises a sequence domain of SEQ IDNO
 239. 26. A gene therapy method according to claim 25, which is an invitro gene therapy.
 27. A gene therapy method according to claim 25,which is an in vivo gene therapy.
 28. A gene therapy method according toclaim 25, wherein the oligonucleotide is comprised in an expressionvector.
 29. A gene therapy method according to claim 25, wherein theexpression vector is comprised in a cell.
 30. A process for theidentification of pain-modulating substances comprising the followingprocess steps: (a) providing a test cell which comprises at least oneoligonucleotide comprising the sequence according to one of SEQ ID NOs2-10, SEQ ID NOs 19-27, SEQ ID NOs 30-38, SEQ ID NOs 47-55, SEQ ID NOs64-72, SEQ ID NOs 81-89, SEQ ID NOs 98-106, SEQ ID NOs 115-123, SEQ IDNOs 132-140, SEQ ID NOs 149-157, SEQ ID NOs 160-168, SEQ ID NOs 178-186,SEQ ID NOs 195-203, SEQ ID NOs 212-220, SEQ ID NOs 223-231 or SEQ ID NOs240-248, wherein each of SEQ ID NOs 2-10 comprises a sequence domain ofSEQ ID NO 1, each of SEQ ID NOs 19-27 comprises a sequence domain of SEQID NO 18, each of SEQ ID NOs 30-38 comprises a sequence domain of SEQ IDNO 29, each of SEQ ID NOs 47-55 comprises a sequence domain of SEQ ID NO46, each of SEQ ID NOs 64-72 comprises a sequence domain of SEQ ID NO63, each of SEQ ID NOs 81-89 comprises a sequence domain of SEQ ID NO80, each of SEQ ID NOs 98-106 comprises a sequence domain of SEQ ID NO97, each of SEQ ID NOs 115-123 comprises a sequence domain of SEQ ID NO114, each of SEQ ID NOs 132-140 comprises a sequence domain of SEQ ID NO131, each of SEQ ID NOs 149-157 comprises a sequence domain of SEQ ID NO148, each of SEQ ID NOs 160-168 comprises a sequence domain of SEQ ID NO159, each of SEQ ID NOs 178-186 comprises a sequence domain of SEQ ID NO177, each of SEQ ID NOs 195-203 comprises a sequence domain of SEQ ID NO194, each of SEQ ID NOs 212-220 comprises a sequence domain of SEQ ID NO211, each of SEQ ID NOs 223-231 comprises a sequence domain of SEQ ID NO222, or each of SEQ ID NOs 240-248 comprises a sequence domain of SEQ IDNO 239, (b) providing a control cell that does not comprise saidoligonucleotide, (c) incubating a candidate substance under suitableconditions with the test cell, or a preparation made from the test cell,which has synthesized at least one vanilloid receptor, (d) measuring thebinding of the test substance to the receptor synthesized by the testcell, or measuring at least one functional parameter of the receptormodified by binding of the test substance onto the receptor, (e)measuring the binding of the test substance to the receptor synthesizedby the control cell, or measuring at least one functional parameter ofthe receptor modified by binding of the test substance onto thereceptor, (d) identifying a substance by a difference between themeasured value for the test cell and that for the control cell.
 31. Amethod according to claim 30, wherein the vanilloid receptor is a VR-1receptor.